- Home
- MVBF vs AVIR Comparison
MVBF vs AVIR Comparison
Compare MVBF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVBF
- AVIR
- Stock Information
- Founded
- MVBF 1997
- AVIR 2012
- Country
- MVBF United States
- AVIR United States
- Employees
- MVBF N/A
- AVIR N/A
- Industry
- MVBF Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- MVBF Finance
- AVIR Health Care
- Exchange
- MVBF Nasdaq
- AVIR Nasdaq
- Market Cap
- MVBF 278.3M
- AVIR 273.0M
- IPO Year
- MVBF N/A
- AVIR 2020
- Fundamental
- Price
- MVBF $23.45
- AVIR $3.74
- Analyst Decision
- MVBF Buy
- AVIR Hold
- Analyst Count
- MVBF 3
- AVIR 1
- Target Price
- MVBF $24.67
- AVIR $6.00
- AVG Volume (30 Days)
- MVBF 49.5K
- AVIR 413.9K
- Earning Date
- MVBF 07-28-2025
- AVIR 08-06-2025
- Dividend Yield
- MVBF 2.93%
- AVIR N/A
- EPS Growth
- MVBF N/A
- AVIR N/A
- EPS
- MVBF 1.46
- AVIR N/A
- Revenue
- MVBF $146,101,000.00
- AVIR N/A
- Revenue This Year
- MVBF N/A
- AVIR N/A
- Revenue Next Year
- MVBF $14.22
- AVIR N/A
- P/E Ratio
- MVBF $16.07
- AVIR N/A
- Revenue Growth
- MVBF N/A
- AVIR N/A
- 52 Week Low
- MVBF $15.59
- AVIR $2.46
- 52 Week High
- MVBF $25.24
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- MVBF 84.28
- AVIR 75.75
- Support Level
- MVBF $20.26
- AVIR $3.43
- Resistance Level
- MVBF $23.51
- AVIR $3.80
- Average True Range (ATR)
- MVBF 0.56
- AVIR 0.14
- MACD
- MVBF 0.21
- AVIR 0.03
- Stochastic Oscillator
- MVBF 97.06
- AVIR 78.46
About MVBF MVB Financial Corp.
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).